HealthQuill Singapore
US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which is under trial, for treating chronic kidney diseases.
Drugs Health Pharma

Vertex, China’s Zai to develop, commercialise kidney disease drug

US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which.

Read More
AstraZeneca plans to build a $1.5 billion facility to make antibody-drug conjugates in Singapore, the company announced in a statement.
Drugs Health Pharma

AstraZeneca plans to build $1.5 billion drug making facility in Singapore 

HQ Team May 20, 2024: AstraZeneca plans to build a $1.5 billion facility to make antibody-drug conjugates in Singapore, the company announced in.

Read More
The WHO has updated the EG.5 variability of the COVID-19 virus to a ‘variant of interest’ — with genetic changes that are predicted or known to affect virus characteristics, such as transmissibility, virulence, antibody evasion, susceptibility to therapeutics and detectability.
Drugs Health Pharma

WHO labels Covid-19 variant EG.5 as ‘variant of interest’; cases rise

HQ Team August 10, 2023: The WHO has updated the EG.5 variability of the COVID-19 virus to a ‘variant of interest’ — with.

Read More
India's Jain Irrigation merged its international irrigation business with Israel-based Rivulis Pte. through a cash and stock transaction to reduce consolidated debt, according to a BSE filing.
Climate Health

Jain Irrigation merges with Israel’s Rivulis to cut consolidated debt

India's Jain Irrigation merged its international irrigation business with Israel-based Rivulis Pte. through a cash and stock transaction to reduce consolidated debt, according.

Read More